As elevated level of CA125 is the hallmark of ovarian cancer diagnosis and frequently observed in recurrent disease, enhanced expression of CA125 in paclitaxel-treated tumor cells may suggest priming of the residual cells for recurrence. The gene discussed is MUC16; the disease is ovarian cancer.